DermTech Closes Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

January 11, 2021

All of the shares in the offering were sold by DermTech.

DermTech, Inc. closed its previously announced underwritten public offering of 4,872,881 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase up to 635,593 additional shares, at a price to the public of $29.50 per share, the company reports.

DermTech’s aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $143.7 million. All of the shares in the offering were sold by DermTech.

Cowen and William Blair acted as joint book-running managers for the offering. BTIG, Craig-Hallum and Oppenheimer & Co. acted as lead managers for the offering, and Lake Street Capital Markets acted as co-manager for the offering.

The offering was made only by means of a written prospectus and related prospectus supplement forming part of DermTech’s shelf registration statement on Form S-3 (File No. 333-248642) that was filed with the Securities and Exchange Commission (the “SEC”) on September 8, 2020 and declared effective by the SEC on September 17, 2020. The final prospectus supplement and accompanying prospectus are available at the SEC’s website located at

The DermTech Melanoma Test uses a proprietary process to painlessly extract RNA and DNA from skin tissue samples to find genomic markers of melanoma.

Facebook Comments


We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free